Companion Diagnostics Market worth $8,730.7 Million by 2019

The report "Companion Diagnostics Market by Technology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer) & End-user (Pharmaceutical Companies, Reference Lab)- Global Trends & Forecasts to 2019". The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3136.9 million in 2014, at a CAGR of 22.7% during the forecast period (2014 to 2019).

Browse 57 market data tables with 36 figures spread through 142 pages and in-depth TOC on "Companion Diagnostics Market"

Early buyers will receive 10% customization on this report.

"Next-generation Sequencing (NGS)-based Companion Diagnostic Tests to Capture a Larger Market Share in Chronic and Life Threatening Diseases in the Future"

Advanced technologies such as next-generation sequencing (NGS), increasing adoption of companion diagnostic kits/tests by the pharmaceutical industry and encouragement from regulatory bodies are expected to boost the global market.

Read More | Download PDF Brochure@

Increasing costs of drug discovery; continuous focus on customized medicines for cancer; infectious, cardiovascular, neurological, and autoimmune diseases; and the need for technically advanced diagnostics has stimulated pharmaceutical firms to enter into the market. In 2013, many new molecular entities (NMEs) were approved by a pharmacogenomic biomarker from the FDA.

However, non-validated home brew tests employed by reference laboratories pose a major threat to validated companion diagnostic kits globally, as they are easily available and have faster approval procedures. In addition, different reimbursement policies followed by different regions may hinder the growth of the market.

Get The Sample Copy Of This Report:

NGS-based companion diagnostics is one of the major factors that will drive the market owing to its capability of identifying multiple genes at a single time. This in turn encouraged the adoption of diagnostic tests in the earlier clinical phase and ensured accurate treatments.

Currently, NGS-based companion diagnostic tests are available for cystic fibrosis and the companion diagnostic manufacturers are engaged in developing tests for other chronic and life threatening diseases. To capture this market, pharmaceutical firms are striving to enter into the global market through strategic acquisitions and collaborations with NGS platform diagnostic firms. Moreover, the end results of NGS is superior as compared to other technologies, as NGS provides a wider definition of genome sequencing that will fuel the adoption of NGS-based companion diagnostic in the future.

This study also illustrates the major market players who have made a remarkable contribution in the global market. The major players of this market are Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), Thermo Fisher Scientific Inc. (U.S.), and QIAGEN N.V. (Netherlands).

Browse Related Reports:

Molecular Diagnostics Market by Application (Infectious Disease, Oncology, Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, Laboratories), Product (Instruments, Reagent, Service, Software) - Global Forecasts to 2018.

In Vitro Diagnostic (IVD) Market [Instruments, Reagents & Data Management Systems] [Technique (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Haematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] - Forecast To 2017.

About MarketsandMarkets:

MarketsandMarkets is the world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Subscribe Reports from Healthcare Domain @

Mr. Rohan

Unit No. 802, 8th Floor,

Tower - 7, Magarpatta City SEZ,

Hadapsar, Pune – 411013,

Maharashtra, India.

Tel: +1-888-6006-441.

Visit MarketsandMarkets Blog @

Connect with us on LinkedIn @